HEINEKEN Holding NV
Heineken Holding N.V. reports transactions under its current share buyback programme
Heineken Holding N.V. reports transactions under its current share buyback programme
Heineken Holding N.V. reports transactions under its current
share buyback programme
Amsterdam, 10 March 2025 - Heineken Holding N.V. (EURONEXT:HEIO; OTCQX: HKHHY), hereby reports transaction details related to the first tranche of up to circa €375 million tranche of its share buyback programme of up to circa €750 million as communicated on 12 February 2025.
From 3 March 2025 up to and including 7 March 2025 a total of 65,218 shares was repurchased on exchange at an average price of € 70.33.
Up to and including 7 March 2025, a total of 211,330 shares was repurchased under the share buyback programme for a total consideration of € 14,682,814.
Heineken Holding N.V. publishes on a weekly basis, every Monday, an overview of the progress of the share buyback programme on its website: https://www.heinekenholding.com/investors/share-information/share-buyback-programme
Enquiries |
Media Heineken Holding N.V. | ||
Kees Jongsma | ||
tel. +31 6 54 79 82 53 | ||
E-mail: cjongsma@spj.nl | ||
Media | Investors | |
Christiaan Prins | Tristan van Strien | |
Director of Global Communications | Global Director of Investor Relations | |
Marlie Paauw | Lennart Scholtus / Chris Steyn | |
Corporate Communications Lead | Investor Relations Manager / Senior Analyst | |
E-mail: pressoffice@heineken.com | E-mail: investors@heineken.com | |
Tel: +31-20-5239355 | Tel: +31-20-5239590 |
Regulatory information:
This press release is issued in connection with the disclosure and reporting obligations as set out in Article 5(1)(b) Regulation (EU) 596/2014 and Article 2(2) of the Commission Delegated Regulation (EU) 2016/1052 that contains technical standards for buyback programs.
Editorial information:
Heineken Holding N.V. engages in no activities other than its participating interest in Heineken N.V. and the management or supervision of and provision of services to that company. HEINEKEN is the world's most international brewer. It is the leading developer and marketer of premium and non-alcoholic beer and cider brands. Led by the Heineken® brand, the Group has a portfolio of more than 340 international, regional, local and specialty beers and ciders. With HEINEKEN’s over 85,000 employees, HEINEKEN brews the joy of true togetherness to inspire a better world. HEINEKEN’s dream is to shape the future of beer and beyond to win the hearts of consumers. HEINEKEN is committed to innovation, long-term brand investment, disciplined sales execution and focused cost management. Through "Brew a Better World", sustainability is embedded in the business. HEINEKEN has a well-balanced geographic footprint with leadership positions in both developed and developing markets. HEINEKEN operates breweries, malteries, cider plants and other production facilities in more than 70 countries. Most recent information is available on www.heinekenholding.com and www.theheinekencompany.com and follow HEINEKEN on LinkedIn and Instagram.
Attachment
Documents
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
798 Art District26.4.2025 14:44:55 CEST | Press release
798 Art District and Beijing International Film Festival Jointly Launch “Art Lights the Screen” – A Cultural Feast of Film and Art
Atlantic Petroleum P/F26.4.2025 14:32:40 CEST | Press release
Summons for the Annual General Meeting of P/F Atlantic Petroleum
Financière de Tubize SA26.4.2025 08:00:00 CEST | Press release
Financière de Tubize - Dividend approval
MoonLake Immunotherapeutics AG25.4.2025 22:05:00 CEST | Press release
MoonLake Immunotherapeutics to host a Capital Markets Day on Tuesday, April 29
T-knife Therapeutics25.4.2025 19:00:00 CEST | Press release
T-knife Therapeutics Presents Preclinical Data at the American Association for Cancer Research (AACR) Annual Meeting Demonstrating a Potential Best-in-Class PRAME Targeted TCR-T Therapy
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom